Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy agree Actos generic deal

Ranbaxy Laboratories has reached an agreement with Takeda to launch a generic version of its blockbuster diabetes drug, Actos, in the US

Ranbaxy Laboratories has reached an agreement with Takeda Pharmaceuticals to launch a generic version of its blockbuster diabetes drug treatment, Actos (pioglitazone hydrochloride), in the US.

The deal will see the two companies resolve patent litigation that has been outstanding since makers of Actos, Takeda sued Ranbaxy, along with Watson Pharmaceuticals and Mylan Laboratories, in 2003 over potential generic versions.

Full terms of the settlement have yet to be disclosed, though Takeda will grant Ranbaxy, India's largest pharmaceutical company, a non-exclusive royalty free license to its US patents covering Actos. Ranbaxy will be allowed to launch its generic version in the US on August 17, 2012, or earlier under certain circumstances.

Takeda had previously announced a similar agreement with Watson Pharmaceuticals regarding their own generic version of Actos.

Jim Meehan, vice president of sales and distribution for Ranbaxy Pharmaceuticals Inc (RPI), part of the Ranbaxy family, said: "This agreement will allow RPI to bring to patients with diabetes a generic alternative in this important therapeutic area."

Actos is one of Takeda's biggest selling drugs, achieving around $3.4bn in brand sales for 2009.

16th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics